pseudoephedrine hydrochloride + triprolidine hydrochloride: clinical use

Prescribing considerations

• Confirm that both congestion and histamine-mediated symptoms require treatment; avoid duplication with other cold or allergy products.
• Assess cardiovascular disease, blood pressure, renal and hepatic function, diabetes, thyroid disease, glaucoma, urinary retention and interacting medicines.
• Consider triprolidine-related sedation and anticholinergic burden, especially in older or susceptible patients.
• Advise immediate discontinuation and assessment for symptoms suggesting PRES, RCVS, ischaemic colitis, ischaemic optic neuropathy or severe skin reaction.

Contraindications and cautions

• Hypersensitivity to either active ingredient or an excipient
• Current or recent MAOI or RIMA treatment
• Other sympathomimetic decongestants or beta blockers
• Cardiovascular disease
• Severe or uncontrolled hypertension
• Diabetes mellitus
• Phaeochromocytoma
• Hyperthyroidism
• Closed-angle glaucoma
• Severe acute or chronic kidney disease or renal failure

Monitoring

• No routine laboratory monitoring is specified for short-term use.
• Where clinically relevant, monitor blood pressure, heart rate, alertness, urinary symptoms and neurological, visual, gastrointestinal or severe skin symptoms.

Clinical pharmacology

Pseudoephedrine has direct and indirect sympathomimetic activity that produces upper-airway decongestion. Triprolidine is a competitive H1-receptor antagonist with mild central nervous system depressant and anticholinergic properties.

Formulation and product differences

• The selected product is an oral tablet containing pseudoephedrine and triprolidine as its only active ingredients.
• The tablet contains lactose and is unsuitable for certain rare hereditary disorders of galactose or lactose handling.
• Products containing additional active ingredients have different indications, precautions and interaction profiles and should not be treated as equivalent.